The study and its comparison
Two hundred thirty-one patients with elevated baseline creatinine undergoing coronary angiography or intervention were randomized to vitamin C or placebo around the procedure. [1]
The trial’s creatinine-defined nephropathy endpoint occurred in about nine percent versus twenty percent. Measurements were taken two to five days after contrast exposure. [1]
What the finding establishes
This is a specific coronary-procedure setting and biochemical endpoint, not proof of fewer long-term dialysis events or safety before all operations. Background care and clinical practice have evolved since this 2004 trial. Funding and conflicts were not established from the abstract. Its research regimen should not be copied without the procedure team’s direction. [1]
A hypothetical distinction
Imagine fewer patients cross a short-term laboratory threshold. A long-term kidney-outcome claim would require further evidence.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.